Mongolia vs Ukraine: Average cost of drugs for extensively drug-resistant tuberculosis
Mongolia
1,900 constant 2022 US$
in 2024
Ukraine
1,566 constant 2022 US$
in 2024
Mongolia rank
28th
Ukraine rank
31st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Mongolia
- Ukraine
How they compare
Mongolia currently reports 1,900 constant 2022 US$ against 1,566 constant 2022 US$ in Ukraine, a difference of 334 constant 2022 US$.
That makes Mongolia's figure about 1.2 times Ukraine's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Mongolia ahead.
Mongolia ranks 28th and Ukraine ranks 31st of 56 countries.
Across the 2 decades both report, Mongolia averaged higher in 1 and Ukraine in 1.
Head to head by decade
| Decade | Mongolia | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 14,667 constant 2022 US$ | 5,398 constant 2022 US$ | 9,269 constant 2022 US$ | Mongolia |
| 2020s | 2,120 constant 2022 US$ | 3,686 constant 2022 US$ | 1,566 constant 2022 US$ | Ukraine |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Mongolia or Ukraine?
- Mongolia, at 1,900 constant 2022 US$ against 1,566 constant 2022 US$ in Ukraine as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Mongolia and Ukraine?
- 334 constant 2022 US$, with Mongolia ahead.
- How many years of comparable data are there for Mongolia and Ukraine?
- 8 years are reported by both, from 2017 to 2024.
- How do Mongolia and Ukraine rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Mongolia ranks 28th and Ukraine ranks 31st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.